- Home
- THC vs GH Comparison
THC vs GH Comparison
Compare THC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THC | GH |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 20.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | THC | GH |
|---|---|---|
| Price | $262.33 | $168.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 19 |
| Target Price | ★ $237.90 | $119.79 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 17.81 | N/A |
| Revenue | ★ $18,479,000,000.00 | $982,021,000.00 |
| Revenue This Year | $4.36 | $33.30 |
| Revenue Next Year | $1.89 | $28.27 |
| P/E Ratio | $14.41 | ★ N/A |
| Revenue Growth | 0.91 | ★ 32.88 |
| 52 Week Low | $157.58 | $53.29 |
| 52 Week High | $265.32 | $176.58 |
Technical Indicators
Market Signals| Indicator | THC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 69.53 | 55.63 |
| Support Level | $187.21 | $152.64 |
| Resistance Level | $262.68 | $174.08 |
| Average True Range (ATR) | 10.14 | 7.70 |
| MACD | 2.86 | 0.12 |
| Stochastic Oscillator | 88.29 | 46.81 |
Price Performance
Historical ComparisonAbout THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (50 as of December 2025) and hundreds of ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.